Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights
Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights
Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis
Phase 3 clinical trial of ZERVIATE in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China
U.S. prescriptions for VYZULTA
TM by 56% over Q3 2020
Q4 2020 net revenue of €5.8 million, full year 2020 net revenue of €8.9 million and cash of €47.8 million at December 31, 2020 January 20, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q4 2020 for Nicox SA and its subsidiaries (the Nicox Group ), as well as key expected value-inflection milestones in 2021.